Brief: FDA Grants Fast Track Designation For Paradigm Biopharmaceuticals Phase III Osteoarthritis Program
13/04/2022 17:47
April 13 (Reuters) - Paradigm Biopharmaceuticals Ltd
PAR.AX :
* FDA GRANTS FAST TRACK DESIGNATION FOR PARADIGM
BIOPHARMACEUTICALS PHASE III OSTEOARTHRITIS PROGRAM
Source text for Eikon: ID:nPnbYwNRWa
Further company coverage: PAR.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paradigm Biopharmaceuticals
See all newsBrief: Paradigm Biopharmaceuticals Says Board Initiates Voluntary Administration
Brief: Paradigm Biopharmaceuticals Seeks Trading Halt
Australia's Paradigm Biopharmaceuticals slips on discounted placement
Brief: Paradigm Biopharmaceuticals Says Co Completes A$14 Mln Placement
Brief: Paradigm Biopharmaceuticals Requests Trading Halt